We are live on ! Find out more
APOPW

Cellect Biotechnology Ltd. Warrants to Purchase ADRs
APOPW

Delisted

APOPW was delisted on the 3rd of August, 2021.

Back to rankings

2 hedge funds and large institutions have $403K invested in Cellect Biotechnology Ltd. Warrants to Purchase ADRs in 2017 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more capital invested

Capital invested by funds: $373K → $403K (+$30K)

0% more funds holding

Funds holding: 2 → 2 (0)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
-$75K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$26.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
AFM
1
Anson Funds Management
Texas
$346K -$75K -73,108 -64%
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$57K -$26.1K -25,438 -52%

APOPW Hedge Fund Activity: Q1 2017 in Review

2 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Cellect Biotechnology Ltd. Warrants to Purchase ADRs (APOPW) for Q1 2017, worth a combined $403K — up 8% from $373K a quarter earlier.

Fund positioning in APOPW was balanced in Q1 2017: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.

The largest seller was Anson Funds Management, cutting an estimated $75K.

  • 2 institutional investors held Cellect Biotechnology Ltd. Warrants to Purchase ADRs (APOPW) as of Q1 2017, unchanged from Q4 2016.
  • Funds reported $403K of Cellect Biotechnology Ltd. Warrants to Purchase ADRs stock for Q1 2017, up 8% quarter-over-quarter.
  • 0 funds opened new Cellect Biotechnology Ltd. Warrants to Purchase ADRs positions in Q1 2017 and 0 closed out.
  • The largest Cellect Biotechnology Ltd. Warrants to Purchase ADRs seller in Q1 2017 was Anson Funds Management, an estimated $75K sold.

Based on aggregated 13F filings for Q1 2017.